Form 4: Kiniksa Pharmaceuticals Executive Reports Stock Transactions

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reports multiple transactions involving Class A Ordinary Shares, including acquisitions and disposals, executed under a 10b5-1 plan.

Summary

• On May 7, 2025, Michael R. Megna, the Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares.
• Megna acquired 229 shares at $8.83, 2,998 shares at $15.5, and 14,420 shares at $11.97.
• He also disposed of 17,647 shares at $26.69.
• These transactions were executed under a pre-arranged 10b5-1 plan adopted on July 24, 2024.
• Following these transactions, Megna beneficially owns 32,546 Class A Ordinary Shares.
• The transactions also involved the exercise of share options at prices of $8.83, $15.5 and $11.97.
• Megna directly owns all the reported securities.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions by an officer. The transactions themselves don't necessarily indicate a positive or negative sentiment, as they are conducted under a pre-arranged plan.

Positives

• The reporting person's transactions are being conducted under a pre-arranged 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a key company officer.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Michael R. Megna, Class A Ordinary Shares, Form 4, SEC, 10b5-1 plan, insider trading, share options, stock transactions